Amer Zeidan, MBBS

Amer Zeidan, MBBS, MD, discusses whether the expanding lower-intensity arsenal has narrowed the definition of a patient with AML who is unfit.

Amer Zeidan, MBBS, MD, discusses how mutation status and physical fitness factor into frontline AML regimen selection.

Amer Zeidan, MBBS, MD, discusses why real-world venetoclax dose modifications do not appear to compromise response durability in AML.

Amer Zeidan, MBBS, MD, discusses how the newly approved all-oral decitabine/cedazuridine plus venetoclax regimen fits into frontline AML care.

Education and reinforcement may improve luspatercept dose titration and persistence in community practice.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed sequencing options like luspatercept after ESA failure in RS-negative lower-risk MDS.

Imetelstat may be considered as a frontline option for patients with a high transfusion burden, said Amer Zeidan, MBBS, MD.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discussed using IPSS-M criteria to detect hidden high-risk biology in lower-risk MDS.

Amer Zeidan, MBBS, MD, and Raji Shameem, MD, discuss how long-term COMMANDS data support the use of luspatercept.

Amer Zeidan, MBBS, MD, discussed when to start luspatercept at the full 1.75 mg/kg dose in lower-risk MDS based on the MAXILUS trial.

In this concluding segment, the panel reflects on the evolving landscape of treatment for myeloid malignancies, including high-risk MDS and CML, with a focus on oral HMAs. Dr. Fazal emphasizes the importance of clinical trial participation, noting that although some combination therapies may not show overall superiority, subsets of patients demonstrate meaningful benefit, highlighting the need for ongoing research and novel therapeutic strategies.

This segment focuses on practical strategies for managing high-risk CML, particularly in patients with proliferative and cytopenic symptoms. The discussion begins with balancing symptomatic management, such as fatigue, early satiety, splenomegaly, anemia, and thrombocytopenia, alongside disease-directed therapy.

The panel discusses the case of a 67-year-old female patient diagnosed with high-risk chronic myelomonocytic leukemia (CML-1) who presents with intermediate risk scores and abnormal blood counts, including elevated white blood cells, mild thrombocytopenia, and anemia.

This segment continues the discussion of high-risk MDS management, focusing on how clinicians define failure of HMAs and determine next steps in therapy, particularly in patients with TP53 mutations.

This case-based discussion illustrates the practical management of a 72-year-old patient with high-risk MDS and TP53 mutation.

This segment explores the critical role of patient support programs, insurance navigation, and balancing the convenience of oral HMAs with ongoing clinical oversight.

Explore the practical challenges of using oral hypomethylating agents, focusing on safety, access, and effective patient management strategies.

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes.

Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.

Explore the latest advancements in oral hypomethylating agents for MDS and CMML, emphasizing their efficacy, patient convenience, and treatment strategies.